Please assess the completion status of the following clinical trial:

Trial Title: Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Stage IV melanoma arising from a primary cutaneous site or metastatic from an unknown primary site with no evidence of disease (NED) after surgery or radiation therapy (conducted within 8 weeks before enrolment)~* Signed written informed consent~* Known BRAF status~* Subjects must be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other requirements of the study~* Minimum life expectancy of five years excluding their melanoma diagnosis~* ECOG performance status of 0 or 1~* Tumor tissue from the resected site of disease must be provided for biomarker analyses. In order to be randomized a subject must have a PD-L 1 expression classification (positive (≥ 5% tumor cells expressing PD-L1) or negative (\< 5% tumor cells expressing PD-L1)). If an insufficient amount of tumor tissue from the resected site is provided for analysis, acquisition of additional archived tumor tissue (block and/or slides) for the biomarker analyses is required.~* Prior radiotherapy must have been completed at least 2 weeks prior to study drug administration~* Required laboratory values~* Negative pregnancy test for female subjects and effective contraception (Pearl-Index \<1) for both male and female subjects if the risk of conception exists~Exclusion Criteria:~* History of primary uveal or mucosal melanoma~* Prior therapy with CTLA4 or PD1 antibodies~* The patient has psychiatric or addictive disorders that may compromise his/her ability to give informed consent or to comply with the trial procedures.~* Lack of availability for clinical follow-up assessments.~* Any immunosuppressive therapy given within the past 30 days prior to study drug administration (excluding physiologic steroid hormone replacement)~* Other malignancies within the past five years requiring treatment except basal or squamous skin carcinomas or carcinoma in situ of the cervix~* Serious cardiac, gastrointestinal, hepatic or pulmonary disease reducing life expectancy to less than five years~* Patients with serious intercurrent illness, requiring hospitalization.~* Other serious illnesses, e.g., serious infections requiring antibiotics or bleeding disorders.~* The patient is known to be positive for Human Immunodeficiency Virus (HIV) or other chronic infections (HBV, HCV) or has another confirmed or suspected immunosuppressive or immunodeficient condition.~* Known hypersensitivity reaction to any of the components of study treatment~* Pregnancy (absence to be confirmed by ß-HCG urinary test, minimum sensitivity 25IU/L or equivalent units of HCG)) or lactation period~* Women of childbearing potential (WOCBP): Refusal or inability to use effective means of contraception (Pearl-Index \<1). WOCBP will be instructed to adhere to contraception until 31 weeks after the last dose of investigational product~* Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year (Pearl-Index \<1). Men receiving Nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception until 31 weeks after the last dose of investigational product~* Known alcohol or drug abuse~* Participation in another clinical study and use of any investigational or non-registered product (drug or vaccine) within the 30 days before registration~* Significant disease or condition which, in the investigator's opinion, would exclude the patient from the study~* Legal incapacity or limited legal capacity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nivolumab + Placebo (Type: ACTIVE_COMPARATOR): Nivolumab (3 mg/kg) i.v. every 2 weeks + Placebo instead of Ipilimumab on weeks 1, 4, 7 and 10 + Placebo instead of Nivolumab on weeks 4 and 10
- Nivolumab + Ipilimumab (Type: EXPERIMENTAL): Nivolumab (1 mg/kg) and Ipilimumab (3 mg/kg) i.v. every 3 weeks for 4 doses. Both study drugs are administered on the same day over the first 12 weeks + Placebo instead of Nivolumab on weeks 3, 5, 9 and 11. After week 12: Nivolumab as maintenance and at a dose of 3 mg/kg IV every 2 weeks for up to 1 year after initial dosing (of the combination) or until PD.
- Double Placebo Control (Type: PLACEBO_COMPARATOR): Placebo instead of Nivolumab and Placebo instead of Ipilimumab i.v. every 3 weeks for 4 doses. Both placebos are administered on the same day over the first 12 weeks + Placebo instead of Nivolumab on weeks 3, 5, 9 and 11. After week 12 Placebo instead of Nivolumab as maintenance and applied as IV every 2 weeks for up to 1 year after initial dosing (of the combination) or until PD.

Based on this trial design, predict the completion outcome and termination type (if applicable).